Introduction {#s1}
============

Transient Receptor Potential Melastatin 3 (TRPM3) is a Ca^2+^ permeable, non-selective cation channel activated by heat ([@bib30]) and chemical activators such as the neurosteroid pregnenolone sulfate (PregS) ([@bib31]) and the synthetic compound CIM0216 ([@bib14]). TRPM3 is a well-established temperature sensor in peripheral sensory neurons of the dorsal root ganglia (DRG); its genetic deletion in mice leads to defects in noxious heat sensation as well as reduced inflammatory heat hyperalgesia ([@bib30]; [@bib29]). Inhibitors of TRPM3 also reduced both acute heat sensation and inflammatory heat hyperalgesia ([@bib26]; [@bib19]). While TRPM3^-/-^ mice show defects in noxious heat sensation, the channel shows increased activity well below the noxious range, when temperature is increased from 15°C to 26°C, with further increases in activity at 37°C ([@bib30]). TRPM3 is also inhibited by activation of Gi-coupled receptors such as μ-opioid receptors and GABA~B~ receptors in DRG neurons, and agonists of those receptors reduced nocifensive reactions to local injection of TRPM3 agonists ([@bib3]; [@bib8]; [@bib24]).

TRPM3 is also expressed in tissues other than peripheral sensory neurons, where its functional roles are not well understood. In pancreatic β-cells, it was shown that application of the TRPM3 agonist PregS induced an increase in insulin secretion ([@bib31]), but TRPM3^-/-^ mice showed no impairment in glucose homeostasis ([@bib30]). TRPM3 is also expressed in vascular smooth muscle cells, and PregS was reported to induce contractile responses in freshly isolated aorta, but the concentration required for this response was higher than the plasma levels of this compound ([@bib21]). TRPM3 is also expressed in various regions of the brain, where its functional role is essentially unexplored ([@bib23]).

Very little is known about the physiological and pathophysiological roles of TRPM3 in humans. A recent paper showed that two missense mutations in TRPM3 are associated with a neurodevelopmental disorder with intellectual disability, hypotonia and epilepsy, pointing to important roles of this channel in the human brain ([@bib10]). Seven of the eight patients had a de novo Val to Met substitution in the S4-S5 loop, while one patient had a Pro to Gln substitution in the extracellular segment of S6. The effects of these mutations on channel function however were not reported.

Here, we tested the functional effects of the two disease-associated mutations using electrophysiology and intracellular Ca^2+^ measurements. We find that both disease-associated mutations render the channel overactive. Both mutants showed constitutive activity that was inhibited by the TRPM3 antagonist primidone. As primidone is a clinically used medication ([@bib19]), our findings offer potential clinical intervention to treat this channelopathy. We also find that the Val to Met substitution in the S4-S5 loop induced a larger left shift in the concentration response relationship to PregS and CIM0216 than the Pro to Gln substitution close to the pore-loop in the extracellular segment of S6. The increase in heat activation on the other hand was more pronounced in the S6 mutant. We conclude that both reported mutants of TRPM3 are gain of function, but the mechanism of increased channel activity is different for the two mutants.

Results {#s2}
=======

Here we used, patch clamp electrophysiology and intracellular Ca^2+^ measurements in HEK293 cells and two-electrode voltage clamp electrophysiology in *Xenopus* oocytes to study the effects of disease-associated mutations on TRPM3 function. TRPM3 has a large number of splice variants ([@bib23]), but there is no information available which splice variants are expressed in the human brain, and relatively little is known about the functional differences between splice variants. To ensure that our results do not only apply to one variant, we used two commonly used and well-characterized splice variants of TRPM3 in our experiments. In HEK293 cells, we expressed the human orthologue of the most studied mouse variant TRPM3α2 that was originally cloned from mouse brain ([@bib22]; [@bib30]). In *Xenopus* oocytes, we expressed the human TRPM3 splice variant we used in several previous studies ([@bib2]; [@bib3]), originally described in [@bib13] also called the TRPM3~1325~ variant ([@bib22]).

Most alternatively spliced exons are in the cytoplasmic N-terminus; thus, the numbering of mutated residues varies between splice variants. The more common S4-S5 segment mutant described as V837M ([@bib10]) corresponds to V990M in the hTRPM3 splice variant we expressed in *Xenopus* oocytes, and to V992M in the hTRPM3α2 variant we expressed in HEK293 cells. The S6 mutant P937Q in Dyment et al corresponds to P1090Q in the hTRPM3 variant we used in oocytes, and it is P1092Q in the hTRPM3α2 we used in HEK293 cells. [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} shows the location of these residues in the TRPM3 sequence and putative structure.

First, we co-expressed the Ca^2+^ indicator GCaMP6f ([@bib5]) and the hTRPM3α2 isoform and its mutants in HEK293 cells and performed intracellular Ca^2+^ measurements in a 96-well plate reader. We found that the concentration-response relationship to PregS ([Figure 1A--D](#fig1){ref-type="fig"}) and CIM0216 ([Figure 1E--H](#fig1){ref-type="fig"}) were left shifted in the mutant channels; V992M showed a much larger shift than P1092Q for both agonists. The V992M mutant also showed a larger increase in basal Ca^2+^ levels than P1092Q at room temperature (21°C), and the application of the TRPM3 antagonist primidone decreased basal Ca^2+^ levels for both mutants in a concentration-dependent manner ([Figure 1I--L](#fig1){ref-type="fig"}). Primidone had no effect on basal cytoplasmic Ca^2+^ levels in cells transfected with the wild type TRPM3 indicating negligible basal activity of the wild type channel at room temperature ([Figure 1I](#fig1){ref-type="fig"}). Primidone robustly inhibited Ca^2+^ signals evoked by EC~50~ concentrations of PregS both for wild type and mutant channels ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). We also measured PregS responses at 37°C. Consistent with earlier results ([@bib30]), sensitivity of wild-type TRPM3 to PregS increased at 37°C; the EC~50~ of activation decreased to 0.99 μM at 37°C compared to 7 μM at room temperature ([Figure 1---figure supplement 3A,B](#fig1s3){ref-type="fig"}). Basal Ca^2+^ levels at 37°C were substantially elevated in cells expressing wild-type channels, which is consistent with the low temperature threshold of TRPM3 ([@bib30]). Both mutant channels showed very high basal Ca^2+^ levels, which were not further increased by PregS, indicating substantial Ca^2+^ overload when kept at 37°C continuously ([Figure 1---figure supplement 3C,D](#fig1s3){ref-type="fig"}). Primidone (50 μM) reduced basal Ca^2+^ levels at 37°C in wild type channels and to a smaller extent in the mutant channels ([Figure 1M--P](#fig1){ref-type="fig"}).

![Disease-associated mutations increase agonist sensitivity and basal activity of TRPM3.\
HEK293 cells were transfected with the Ca^2+^ indicator GCaMP6f and the hTRPM3α2 or its mutants, and fluorescence was measured in a 96-well plate reader (Flexstation-3) as described in the Materials and methods section. (**A-C**) Fluorescence traces for TRPM3 (**A**), V992M (**B**) and P1092Q (**C**); the applications of various concentrations of PregS and 2 μM ionomycin are indicated by the arrows. Basal fluorescence before the application of PregS was first subtracted, then the traces were normalized to the fluorescence after the application of ionomycin. Each trace shows the average of four replicates from the same 96-well plate. Measurements were performed at 21°C. (**D**) Hill fits of the concentration dependence of the fluorescence signals evoked by PregS. Symbols represent individual wells from three independent transfections. The EC~50~ values were 7.01 ± 0.69 μM for wild-type channels, 0.32 ± 0.03 μM for V992M and 1.97 ± 0.08 μM for P1092Q. (**E-G**) Fluorescence traces for TRPM3 (**E**), V992M (**F**) and P1092Q (**G**), the applications of various concentrations of CIM0216 and 2 μM ionomycin are indicated by the arrows. Basal fluorescence before the application of CIM0216 was first subtracted, then the traces were normalized to the fluorescence after the application of ionomycin. Measurements were performed at 21°C. (**H**) Hill fits of the concentration dependence of the fluorescence signals evoked by CIM0216. Symbols represent individual wells from two independent transfections. The EC~50~ values were 2.72 ± 0.17 μM for wild-type channels, 0.17 ± 0.02 μM for V992M and 0.88 ± 0.08 μM for P1092Q. (**I-K**) Fluorescence traces for TRPM3 (I), V992M (J) and P1092Q (K), the applications of various concentrations of primidone are indicated by the arrows; traces were not normalized and shown as arbitrary fluorescence units (A.U.). Measurements were performed at 21°C. (**L**) Hill1 fits of the concentration dependence of the inhibition evoked by primidone. Symbols represent mean ± SEM from two independent transfections, five or six wells in each. The IC~50~ values were 2.41 ± 0.74 μM for V992M and 0.64 ± 0.09 μM for P1092Q. (**M-O**) Fluorescence traces for TRPM3 (M), V992M (N) and P1092Q (O), the applications of 50 μM primidone are indicated by the arrows; traces show the average of 16 wells from two independent transfections, normalized to the effect of ionomycin. Measurements were performed at 37°C. (**P**) Summary of the data, Mean ± SEM and scatter plots. Statistical significance was calculated with one-way analysis of variance with Bonferroni post hoc comparison for differences of basal fluorescence values between mutant and wild-type channels. The effect of primidone in wild type and mutant channel was evaluated with paired t-test; the p values for significance are shown above the bars.](elife-55634-fig1){#fig1}

Next, we transfected HEK293 cells with the mutant and wild-type hTRPM3α2 and used fura-2 Ca^2+^ imaging to study the effects of acutely increased temperatures ([Figure 2](#fig2){ref-type="fig"}). We first increased the temperature to 37°C, followed by 10 μM primidone at room temperature to facilitate return of Ca^2+^ to baseline. Then we applied 25 μM PregS (in the absence of primidone), and compared the Ca^2+^ responses induced by 37°C to that induced by PregS. In cells transfected with wild-type TRPM3, the temperature-induced Ca^2+^ response was, on average, 29.4% of that induced by PregS, for the V992M mutant it was 76.5%, whereas for the P1092Q mutant it was \~122.5% ([Figure 2D,E](#fig2){ref-type="fig"}). In cells not expressing TRPM3 increasing temperature to 37°C induced only negligible Ca^2+^ signals (not shown).

![Disease-associated mutations increase temperature activation of TRPM3.\
HEK293 cells were transfected with the human TRPM3α2, or its mutants; fura-2 Ca^2+^ imaging experiments were performed as described in the Materials and methods section. (**A-C**) Averaged fluorescence ratio traces (340 nm/380 nm) for all PregS-responsive cells from one coverslip in cells expressing TRPM3 (**A**), V992M (**B**) and P1092Q (**C**). The cells were first stimulated by increasing the temperature to 37°C, followed by 10 μM primidone at room temperature to facilitate return of Ca^2+^ to baseline, finally 25 μM PregS was applied. (**D**) The change in 340/380 ratio induced by 37°C expressed as a fraction of the response to 25 μM PregS. (**E**) 340/380 ratios at baseline, in response to 37°C and in response to 25 μM PregS. Each symbol represents the average value from all PregS-responsive cells from one coverslip, lines connect data points from the same coverslip. Each coverslips had around 70--80 PregS-responsive cells in the WT group; 35--45 for P1092Q, and 15--25 for V992M. Data were collected from three independent transfections.](elife-55634-fig2){#fig2}

Cytoplasmic Ca^2+^ is an indirect measure of TRPM3 activity, thus next, we performed whole cell patch clamp experiments to compare currents induced by increased temperatures and by PregS. These measurements were performed in the absence of extracellular Ca^2+^ to avoid indirect effects of increased cytoplasmic Ca^2+^ such as Ca^2+^ induced desensitization. We stimulated each cell with a temperature ramp from 23°C to 36°C followed by a saturating concentration of PregS (100 μM) at room temperature ([Figure 3A--C](#fig3){ref-type="fig"}). Since the current amplitudes induced by PregS were highly variable, presumably due to different expression levels of the channel ([Figure 3H](#fig3){ref-type="fig"}), we normalized the currents induced by increased temperatures to those evoked by PregS and plotted these relative currents as a function of temperature ([Figure 3D--F](#fig3){ref-type="fig"}). Figure G shows that the slope of the increase of these currents as a function of temperature were significantly steeper for the P1092Q mutant than for V992M, and both mutants were significantly steeper than the wild type.

![Disease-associate mutations increase temperature sensitivity of TRPM3. HEK293 cells were transfected with the human TRPM3α2, or its mutants; whole-cell patch clamp electrophysiology was performed as descried in the Materials and methods section using a ramp protocol from −100 to 100 mV.\
(**A-C**) Representative measurements, top panels show temperature recordings, bottom panels show currents at 100 mV and −100 mV. The applications of 100 μM PregS are indicated by the horizontal lines. (**D-F**) The heat-induced current amplitudes at 100 mV were normalized to the currents induced by PregS and plotted as a function of the temperature from the same data presented in panels A-C. (**G**) Summary of the slopes of the current increases between 23°C and 33°C determined from linear fits from panels D-F. (**H**) Summary of current amplitudes at 100 and −100 mV induced by increasing the temperature to 25°C, 30°C and 35°C as well as in response to PregS.](elife-55634-fig3){#fig3}

Next, we expressed the wild-type hTRPM3~1325~ and its V990M and P1090Q mutants in *Xenopus* oocytes and performed full concentration response measurements with the TRPM3 agonist PregS. Consistent with our Ca^2+^ measurements, the concentration response relationships for PregS were left-shifted for both mutants compared to wild-type, but the effect of the V990M mutation was much more pronounced than that of the P1090Q ([Figure 4A--D](#fig4){ref-type="fig"}).

![Disease-associated mutations increase sensitivity of TRPM3 to PregS.\
Two electrode voltage clamp experiments in oocytes expressing the hTRPM3~1325~ splice variant and its mutants were performed as described in the Materials and methods section using a ramp protocol from −100 to 100 mV every 0.5 s. (**A-C**) Representative measurements for wild-type (**A**), V990M (**B**) and P1090Q (**C**); top traces show currents at +100 mV, bottom traces at −100 mV, dashed line shows zero current. The applications of different concentrations of PregS (μM) are indicated by the horizontal lines. (**D**) Hill fits of the concentration dependence of the effect of PregS at 100 mV for wild-type and mutant channels. The EC~50~ values were 17.1 ± 0.9 μM for wild-type channels, 0.63 ± 0.05 μM for V990M and 6.94 ± 0.38 μM for P1090Q. (**E-F**) Representative traces for measurements in oocytes injected with cRNA for wild type and mutant channels (1:1 ratio). (**G**) Hill fits of the concentration dependence of the effects of PregS at 100 mV for wild type and mutant channel combinations; symbols represent individual oocytes from two different preparations. The EC~50~ values were 17.8 ± 1.04 μM for wild-type channels, 3.83 ± 0.27 μM for V990M + WT and 12.2 ± 1.1 μM for P1090Q + WT.](elife-55634-fig4){#fig4}

Both disease-associated mutations are de novo, and all known patients are heterozygous. To mimic heterozygous conditions, we co-injected oocytes with wild type cRNA and either mutant in a 1:1 ratio. The PregS dose response was still markedly left shifted for the V990M:TRPM3 combination, but it was only marginally shifted in the P1090Q:TRPM3 combination compared to WT TRPM3 ([Figure 4E--G](#fig4){ref-type="fig"}).

To assess basal current levels, we applied 50 μM primidone at room temperature (20--22°C). Consistent with our Ca^2+^ measurements, primidone evoked a significantly larger inhibition of basal activity in the V990M than in the P1090Q mutant both at 100 and −100 mV ([Figure 4---figure supplement 1B-D](#fig4s1){ref-type="fig"}). Primidone did not induce any inhibition in non-injected oocytes (not shown, n = 5), but it evoked a small reduction in oocytes expressing TRPM3 ([Figure 4---figure supplement 1A,D](#fig4s1){ref-type="fig"}). Current amplitudes induced by 100 μM PregS were not different between the two mutants and wild type, at +100 mV, but the V990M mutants showed somewhat larger amplitudes at −100 mV than the wild type or the P1090Q mutant ([Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}). We also compared the basal current amplitudes before applying any stimuli, and found that oocytes expressing the V990M mutant showed higher currents than those expressing P1090Q, and both mutants had higher basal currents than wild-type TRPM3 ([Figure 4---figure supplement 1F](#fig4s1){ref-type="fig"}).

We also compared the currents induced by increased temperatures to those evoked by PregS in channels expressed in *Xenopus* oocytes ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). We found that the ratio of currents induced by 30°C over those induced by 50 μM PregS were significantly larger in the P1090Q mutant compared to V990M, and both mutants showed significantly larger current ratios than wild type TRPM3. Increasing temperature to 30°C induced negligible currents in non-injected oocytes, but those currents became larger at higher temperatures (not shown), which prevented us from testing higher temperatures in this experimental setting.

TRPM3 has been shown to be inhibited by activation of Gi-coupled receptors via direct binding of Gβγ ([@bib3]; [@bib8]; [@bib24]). To test if the mutations alter receptor-induced inhibition, we co-expressed TRPM3 or its mutants with Gi-coupled muscarinic M2 receptors in *Xenopus* oocytes. [Figure 4---figure supplement 3A--F](#fig4s3){ref-type="fig"} show that when we applied acetylcholine (ACh) to stimulate M2 receptors, it evoked a \~ 50% inhibition of TRPM3 currents induced by 50 μM PregS. The inhibition of the P1090Q mutant was similar to wild type, but the V990M mutant was essentially not inhibited. To test whether the lack of inhibition was due to allosteric effects of the increased sensitivity to PregS, we stimulated the oocytes expressing the V990M mutant with 5 μM PregS where ACh induced a \~ 35% inhibition ([Figure 4---figure supplement 3C,E](#fig4s3){ref-type="fig"}). We also tested inhibition at the EC~50~ of PregS for wild type (17 μM) and mutant channels, 0.6 μM for V990M and 7 μM for P1090Q. [Figure 4---figure supplement 3G-K](#fig4s3){ref-type="fig"} shows that wild type and V990M mutants were inhibited to a similar extent, the P1090Q mutant was inhibited somewhat more than the wild-type channel. These data show that while the V990M mutation affects receptor-induced inhibition at high PregS concentrations, it is not likely to be the primary mechanism of its gain-of-function phenotype.

Discussion {#s3}
==========

Overall, our data show that disease-associated mutations in TRPM3 render the channel overactive. Both mutants showed basal activity even at room temperature, which was reduced by the TRPM3 antagonist primidone. Basal activity of the V992M mutant at room temperature was higher than that of the P1092Q mutant, but at 37°C, the difference in basal activity between the two mutants became negligible. Given the increased constitutive activity of the mutants at body temperature, increased neuronal excitability and/or Ca^2+^-induced neuronal damage is a possible disease-causing mechanism. Primidone is a clinically approved antiepileptic drug; it is thought to exert its effects by being converted to barbiturate by the liver, but it crosses the blood brain barrier ([@bib20]), and directly inhibits TRPM3 activity even below its therapeutic concentration ([@bib19]). Our data showing that primidone inhibited the basal activity of the mutant channels, suggests a potential therapy for this newly described channelopathy.

The V990/V992M mutation showed a larger increase in basal activity at room temperature, and also induced a larger left shift in the concentration response curves of the agonists PregS and CIM0216 than the P1090/1092Q mutation. This is expected if both mutations increase the stability of the open state of the channel, with the V990/992M mutation having a larger effect. If increased open state stability is the only explanation for the over-activity of the mutants, we would expect V990/992M to be also more sensitive to activation by increased temperatures than P1090/1092Q. This is however not what we observed. We consistently find that the P1090/1092Q mutant showed more pronounced activation by increased temperatures than the V990/992M mutant. This indicates that the mechanism of over-activity is different for the two mutants.

These two residues are in different locations; V990/992 is in the S4-S5 linker whereas P1090/1092 is in the outer portion of S6 ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The S4-S5 linker plays essential roles in channel gating, and has been shown to be a hotspot of disease-associated gain-of-function mutations in a number of TRP channels, including TRPV3, TRPV4, TRPM4 and TRPA1 ([@bib15]). This channel segment also plays a role in binding of hydrophobic, or amphipathic ligands in TRPM channels ([@bib16]). For example, in TRPM8 channels the S4-S5 linker is in direct contact with both the cooling agent icilin, and the menthol analog WS12 ([@bib32]). While PregS is thought to activate TRPM3 by directly binding to the channel ([@bib9]), its binding site in the channel is not known, and currently there is no structural information available for TRPM3. Because of the clear increase in basal activity of the V990/992M mutant, it is quite likely that the mutation primarily increased the stability of the open state and the decrease in EC~50~ of agonist activation is a consequence of the change in activation equilibrium constant ([@bib7]). It cannot be excluded, however, that the mutation also affected PregS binding concurrently, given the general role of this segment in ligand binding in TRP channels.

The membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP~2~) is also required for PregS-induced TRPM3 activity ([@bib2]; [@bib27]; [@bib28]). In TRPM8, the equivalent of V990 is two positions upstream from a residue that is in close contact with PIP~2~, and it is 4 and 7 positions downstream from two residues in close contact with icilin and the menthol analog WS12 ([@bib32]; [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). PIP~2~ is located adjacent to the menthol analogue WS12 and the cooling agent icilin in the TRPM8 structures, and menthol has been shown to allosterically affect PIP~2~ activation ([@bib25]). Therefore, it is also possible that the V990/992M mutation affects PregS activation indirectly via PIP~2~. Increased Ca^2+^ levels in cells expressing mutated channels may also modify cellular PI(4,5)P~2~ levels, which may alter channel activity. Differentiating between these possibilities will require future studies.

While the mechanism of temperature activation of TRP channels is not fully understood ([@bib6]; [@bib18]; [@bib1]; [@bib4]), large-scale unbiased mutagenesis studies on TRPV1 ([@bib12]) and TRPV3 ([@bib11]) show that mutations in the pore region and the outer portion of S6 in these channels selectively abolished heat-, but not agonist-induced channel activation. The P1090/1092Q mutation in TRPM3 is located in the outer portion of S6, and it had a stronger effect on heat activation than the V990/992M mutation, therefore it is possible that the primary effect of the P1090/1092Q mutation is increasing heat sensitivity. Increased temperatures synergize with PregS in activating wild-type TRPM3 ([@bib30]), see also [Figure 1---figure supplement 3B](#fig1s3){ref-type="fig"}, therefore it is possible that the increased PregS sensitivity of the P1090/1090Q mutant is secondary to its increased heat activation.

Overall our data show that both disease-associated mutations render TRPM3 overactive, but likely with different mechanisms.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\               Designation                   Source or reference                           Identifiers                                                                   Additional\
  (species) or resource                                                                                                                                                                 information
  --------------------------- ----------------------------- --------------------------------------------- ----------------------------------------------------------------------------- ------------------------------------------------------------
  Recombinant DNA reagent     hTRPM3α2; hTRPM3 variant 10   Genescript                                    NM_001366141.2                                                                In pCDNA3.1(+); tagged with GFP on its N-terminus

  Recombinant DNA reagent     hTRPM3α2-V992M                Genescript                                    NM_001366141.2\                                                               In pCDNA3.1(+); tagged with GFP on its N-terminus
                                                                                                          Modified by V992M mutation                                                    

  Recombinant DNA reagent     hTRPM3α2-P1092Q               Genescript                                    NM_001366141.2\                                                               In pCDNA3.1(+); tagged with GFP on its N-terminus
                                                                                                          Modified by P1092Q mutation                                                   

  Recombinant DNA reagent     hTRPM3~1325~                  Grimm et al 203 JBC, 278, 21493               AJ505026                                                                      Original clone was subcloned into the pGEMSH oocyte vector

  Recombinant DNA reagent     GCaMP6f                       Addgene                                       \# 40755 RRID:[Addgene_40755](https://scicrunch.org/resolver/Addgene_40755)   

  Cell line (human)           HEK293                        ATCC                                          CRL-1573, RRID:[CVCL_0045](https://scicrunch.org/resolver/CVCL_0045)          

  Strain, strain background   *Xenopus* Leavis              Nasco                                         LM00535                                                                       Female frogs to extract oocytes

  Commercial assay or kit     mMessage mMachine             Thermo Fisher Scientific                      Catalogue \# AM1344                                                           In vitro transcription kit

  Commercial assay or kit     Effectene                     Qiagen                                        Catalogue \# 301425                                                           Transfection reagent

  Commercial assay or kit     QuikChange II XL              Agilent Technologies                          Catalogue \# 200522                                                           Site-Directed Mutagenesis Kit

  Chemical compound, drug     Pregnenolone Sulfate          Cayman Chemicals                              Catalogue \#\                                                                 TRPM3 agonist
                                                                                                          21004                                                                         

  Chemical compound, drug     CIM0126                       Calbiochem                                    Catalogue \# 534359                                                           TRPM3 agonist

  Chemical compound, drug     Primidone                     Sigma                                         Catalogue \# p7295                                                            TRPM3 antagonist

  Chemical compound, drug     Ionomycin                     Cayman Chemicals                              Catalogue \#\                                                                 Calcium ionophore\
                                                                                                          56092-81-0                                                                    

  Chemical compound, drug     Fura2-AM                      Invitrogen                                    Catalogue \# F1221\                                                           Calcium indicator;
                                                                                                          RRID:[AB_11156243](https://scicrunch.org/resolver/AB_11156243)                

  Software, algorithm         Origin 2019b                  [Originlab.com](http://Originlab.com)                                                                                       

  Software, algorithm         pClamp10.6                    Molecular Devices                             RRID:[SCR_011323](https://scicrunch.org/resolver/SCR_011323)                  

  Software, algorithm         Image Master 5                Photon Technology International                                                                                             

  Software, algorithm         Prism6                        [www.graphpad.com](http://www.graphpad.com)                                                                                 
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Intracellular Ca^2+^ assay in 96-well plates {#s4-1}
--------------------------------------------

Intracellular Ca^2+^ measurements were performed using a Flexstation-3 96‐well plate reader with rapid well injection (Molecular Devices) as described earlier ([@bib17]) with some modifications. Briefly Human Embryonic Kidney 293 (HEK293) cells were purchased from American Type Culture Collection (ATCC), Manassas, VA, (catalogue number CRL-1573), RRID:[CVCL_0045](https://scicrunch.org/resolver/CVCL_0045); cell identity was verified by STR analysis by ATCC. HEK293 cells were cultured in MEM supplemented with 10% FBS and 100 IU/ml penicillin plus 100 µg/ml streptomycin in 5% CO~2~ at 37°C. Additional cell authentication was not performed, but passage number of the cells was monitored, and cells were used up to passage number 25--30 from purchase, when a new batch of cells was thawed with low passage number; cells were tested for the lack of mycoplasma infection. HEK293 cells were transfected with hTRPM3α2-GFP, or its mutants (200 ng) and GCaMP6 (1 μg) using the Effectene reagent (Qiagen). The human orthologue of the mouse splice variant TRPM3α2 in the pCDNA3.1(+) vector (hTRPM3 variant 10; NM_001366141.2) tagged with GFP on its N terminus, and its V992M and P1092Q mutants were purchased from Genescript, GCaMP6f was a kind gift from Dr. Lawrence Gaspers. After 24 hr, transfected cells were plated on poly-D-lysine coated black-wall clear-bottom 96-well plates and measurements were performed 24--48 hr after plating. Before experiments, the MEM media was replaced with a solution containing (in mM) 137 NaCl, 5 KCl, 1 MgCl~2~, 2 CaCl~2~, 10 HEPES and 10 glucose, pH 7.4 and the plate was measured at around 21°C. GCaMP6 signal was measured at excitation wavelengths 485 nm and fluorescence emission was detected at 525 nm. Sampling interval was 0.86 s and four parallel reads were performed for each condition. For most experiments, 2 μM ionomycin was applied to determine the maximum response. Primidone was purchased form Sigma, CIM0216 from Calbiochem, ionomycin and PregS from Cayman Chemicals. For measurements at 37°C the MEM medium used to culture the cells was replaced with the measurement solution preheated to 37°C, and the plate was placed in the plate reader warmed to 37°C using its built-in temperature controller.

Ca^2+^ imaging experiments {#s4-2}
--------------------------

Ca^2+^ imaging experiments were performed using an Olympus IX-51 inverted microscope equipped with a DeltaRAM excitation light source (Photon Technology International, PTI), as described earlier ([@bib3]). HEK293 cells were transfected with hTRPM3α2-GFP or its mutants using the Effectene reagent (Qiagen). Cells were loaded with 1 μM fura-2 AM (Invitrogen) for 40 min before the measurements at 37°C, and dual-excitation images at 340 and 380 nm excitation wavelengths were detected at 510 nm with a Roper Cool-Snap digital CCD camera. Measurements were conducted at room temperature in extracellular solution containing 137 mM NaCl, 5 mM KCl, 1 mM MgCl~2~, 2 mM CaCl~2~, 10 mM HEPES and 10 mM glucose, pH 7.4. PregS, and primidone were applied with a gravity-driven whole chamber perfusion system. Temperature stimulation was performed using a custom-built system as described earlier ([@bib3]) by pushing bath solution through a spiral tubing immersed in hot water using a 60 ml syringe while monitoring the temperature of the perfusion chamber using a CL-100 Warner Instruments temperature controller. The analogue signal from the CL-100 unit was fed into the Digidata digitizer and the temperature curve was collected in Clampex. Data analysis was performed using the Image Master 5 software (PTI).

Whole cell patch clamp experiments {#s4-3}
----------------------------------

HEK293 cells were transiently transfected with cDNA encoding the hTRPM3α2-GFP, or its mutants with 0.2 µg of constructs using the Effectene reagent (Qiagen) according manufacturer's protocol and were used in experiments 48--72 hr later. Measurements were carried out on GFP positive cells, in an extracellular solution containing (in mM) 137 NaCl, 5 KCl, 1 MgCl~2~, 10 HEPES and 10 glucose, pH 7.4. The intracellular solution contained (in mM) 140 potassium gluconate, 5 EGTA, 1 MgCl~2~, 10 HEPES, and 2 NaATP, pH 7.3. Patch clamp pipettes were prepared from borosilicate glass capillaries (Sutter Instruments) using a P-97 pipette puller (Sutter Instrument) and had a resistance of 2--4 MΩ. In all experiments after formation of GΩ-resistance seals, the whole-cell configuration was established and currents were recorded using a ramp protocol from −100 mV to +100 mV over 500 ms preceded by a −100 mV step for 100 ms; the holding potential was 0 mV, and this protocol was applied once every 1 s. The currents were measured with an Axopatch 200B amplifier, filtered at 5 kHz, and digitized through Digidata 1440A interface. In all experiments, cells that had a passive leak current over 100 pA were discarded. Data were collected and analyzed with the PClamp10.6 (Clampex) acquisition software (Molecular Devices, Sunnyvale, CA), and further analyzed and plotted with Origin 2019b (OrigiLab, Northampton, MA). Heat stimulation was performed as described for the Ca^2+^ imaging experiments.

Two electrode voltage clamp experiments {#s4-4}
---------------------------------------

*Xenopus laevis* oocytes were prepared as described earlier ([@bib2]). All animal procedures were approved by the Institutional Animal Care and Use Committee at Rutgers New Jersey Medical School. In brief, frogs were anesthetized in 0.25% ethyl 3-aminobenzoate methanesulfonate solution (MS222; Sigma-Aldrich); bags of ovaries were removed surgically from the anesthetized frogs. Individual oocytes were obtained by overnight digestion at 16°C in 0.2--0.3 mg/ml type 1A collagenase (Sigma-Aldrich), dissolved in a solution containing 82.5 mM NaCl, 2 mM KCl, 1 mM MgCl~2~, and 5 μM HEPES, pH 7.4 (OR2 solution). The next day the collagenase containing solution was discarded and the oocytes were washed multiple times with OR2 solution. The oocytes were maintained in OR2 solution supplemented with 1.8 mM CaCl~2~, 100 IU/ml penicillin, and 100 μg/ml streptomycin at 16°C. cRNA was transcribed from the linearized human TRPM3 (hTRPM3) cDNA clone ([@bib13]), or its mutants in the pGEMSH vector using the mMessage mMachine kit (Thermo Fisher Scientific). cRNA (40 ng) was microinjected into individual oocytes, using a nanoliter-injector system (Warner Instruments). For combined injection of wild-type and mutant TRPM3 for [Figures 4E--G](#fig4){ref-type="fig"}, 40 μg total cRNA was injected in a 1:1 ratio. The V990M and P1090Q mutants were generated using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies). For the GPCR regulation of these mutants, we injected cRNA of human M2 muscarinic receptors together with TRPM3 or mutants at 1:1 ratio. Oocytes were used for electrophysiological measurements 48--72 hr after microinjection. The hTRPM3~1325~ clone in a mammalian expression vector was provided by C. Harteneck (Eberhard Karls University Tübingen, Tübingen, Germany), and it was subcloned into the pGEMSH oocyte vector using standard molecular biology techniques.

Two electrode voltage clamp experiments were performed as described ([@bib2]). In brief, oocytes were placed in extracellular solution (97 mM NaCl, 2 mM KCl, 1 mM MgCl~2~, and 5 μM HEPES, pH 7.4), and currents were recorded with thin-wall inner filament-- containing glass pipettes (World Precision Instruments) filled with 3 M KCl in 1% agarose. Currents were measured with a ramp protocol from −100 to 100 mV once every 0.5 s with a GeneClamp 500B amplifier and analyzed with the pClamp 9.0 software (Molecular Devices). PregS, ACh and primidone were applied with a gravity driven whole chamber perfusion system. Temperature stimulation was performed the same way as for the whole cell patch clamp and Ca^2+^ imaging experiments in HEK293 cells.

Statistics {#s4-5}
----------

Statistical analysis was performed with Origin 2019b and Prism6. Data are plotted as mean ± SEM and scatter plots. No statistical method was used to predetermine sample sizes, but our sample sizes are similar to those generally employed by the field. Experiments were performed in random order. Data were analyzed with t-test, or one-way analysis of variance with Bonferroni's post hoc test, p values are reported in the figures.

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/100000065National Institute of Neurological Disorders and Stroke NS055159 to Tibor Rohacs.

-   http://dx.doi.org/10.13039/100000057National Institute of General Medical Sciences GM093290 to Tibor Rohacs.

-   http://dx.doi.org/10.13039/100000057National Institute of General Medical Sciences GM131048 to Tibor Rohacs.

This study was supported by grants NSNS055159, GM131048 and GM131048 to TR. The hTRPM3~1325~ clone in a mammalian expression vector was provided by C Harteneck (Eberhard Karls University Tübingen, Tübingen, Germany), the human M2 muscarinic receptor cDNA in the pGEMHE vector was a kind gift from Diomedes Logothetis (Northeastern University, Boston, MA). The authors appreciate the help of Dr. Paula Bartlett and Dr. Andrew Thomas with the 96-well plate reader, and the help of Mr. Michael Motto with the plate reader data analysis.

Additional information {#s5}
======================

No competing interests declared.

Conceptualization, Data curation, Investigation, Writing - original draft, Writing - review and editing.

Investigation, Writing - review and editing.

Conceptualization, Supervision, Funding acquisition, Visualization, Writing - original draft, Writing - review and editing.

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) of Rutgers University, protocol number 17024.

Additional files {#s6}
================

Data availability {#s7}
=================

All data generated or analysed during this study are included in the manuscript and supporting files.

10.7554/eLife.55634.sa1

Decision letter

Islas

Leon D

Reviewing Editor

Universidad Nacional Autónoma de México

Mexico

Islas

Leon D

Reviewer

Universidad Nacional Autónoma de México

Mexico

Xu

Haoxing

Reviewer

University of Michigan

United States

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The function of TRPM3 channels in the brain is not well understood. Recently, single-point mutations in this channel were reported to be the substrate of a form of epilepsy and the authors of the present manuscript now provide functional characterization of those mutants. Their data show that the mutations are gain-of-function events, producing hyperactive channels that as a consequence might contribute to increased excitability leading to the pathological phenotype.

**Decision letter after peer review:**

Thank you for submitting your article \"Disease-associated mutations in TRPM3 render the channel overactive via two distinct mechanisms\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Leon D Islas as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by a Reviewing Editor and Richard Aldrich as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Haoxing Xu (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The physiological functions of TRPM3 ion channels are not well understood. TRPM3 has been shown to act as a peripheral nervous system mild temperature heat-sensor. However, the roles it might play in the central nervous system are less well known. Recently, single point mutations have been identified in TRPM3 from human patients with a neurodevelopmental disability and epilepsy. This finding suggests that TRPM3 channels may play a very important physiological role in normal aspects of motor control and cognition.

This manuscript by Zhao at al., presents an initial characterization of the functional effects of these two mutations on the molecular physiology of hTRPM3. The findings show that both mutants produce a gain-of-function phenotype that partially explains the pathological effects of the mutations.

Essential revisions:

1\) The authors use two \"commonly used\" splice variants of the channel but do not specify if these are the variants expressed in the brain in humans. It seems that both of those are not the same splice variant where the mutations were recently found (Dyment et al., 2019). The authors should perform the analysis on the same splice variant that was sequenced in human patients.

2\) For the V990M and P1090Q, the authors explain that \"temperature sensitivity\" was affected (to different degrees), however, they have not measured temperature sensitivity, that is, the slope of the conductance vs. temperature curve. The authors should be careful to distinguish this measurement from the amplitude of the current at a fixed temperature, which is what they are measuring and may or may not have anything to do with changes in sensitivity.

3\) For the mutant in the pore (P1090Q), the authors should show if the effect of the mutant is also on the single-channel conductance. This is especially true to begin to distinguish the effects on temperature activation.

4\) The effects of the mutations are characterized by comparing magnitude of the current elicited by ligands or temperature with the magnitude of the currents elicited by pregnenolone sulphate (PS), but the authors have not characterized the effects of the mutations on the sensitivity of the channels to PS. It is paramount that the authors show that the mutants have not affected activation by PS since this could severely bias the interpretation of the results.

5\) The interpretation that each one of the mutations affects heat or agonist activation preferentially is not well sustained. Without measuring the actual sensitivity to temperature, you cannot argue that it has been changed by the mutation. The same goes for sensitivity to agonist. Without knowing the binding site you cannot make an argument about sensitivity. Given that TRPM3 seems to be a channel that acts by allosterically coupling its different modalities of activation, and the fact that both mutations increase the basal activity of the channel to some degree, it the seems likely that both mutations just increase the basal open probability without actually affecting the sensitivity to temperature or to ligand. Given that these channels are gated by allosteric mechanisms, increasing the basal open probability will be reflected in increased fractions of current being activated by either temperature or ligand binding. Since the authors do not yet have a handle on the detailed effects of the mutations, they should be careful to offer mechanistic molecular explanations.

6\) Given that the heat sensitivity of TRPM3 might be relevant for central neurons, you may consider testing the PS sensitivity of the mutant channels at the body temperature of 37°C. Results from such experiments would dramatically boost the significance of the study. In addition, it is important to note that the elevated basal Ca^2+^ levels in the mutant-expressing cells may alter the chemo- and thermos- sensitivities indirectly, e.g., by affecting the levels of PIP2, which is known to regulate TRPM3. This should be discussed.

7\) The temperature-dependent gating described here should be thoroughly reviewed. TRPM3 is known to be activated by noxious heat, but in the current study, the channel is robustly activated by 30°C. Judging from the recordings in the Figure 2, it appeared that there was no temperature threshold for activation. Note that the temperature protocol appears to be slightly misaligned with the current traces, such that the currents started to increase prior to temperature elevations. The authors should also consider using the same experimental protocol and X/Y axis to compare WT and mutant channels.

8\) In Figure 4, the experimental design is flawed. The effects of drug inhibition should be separated from those caused by temperature reduction (washout).

9\) The authors analyze one splice variant in oocytes (using electrophysiology) and the second one in HEK cells using calcium imaging. The authors did not provide any reason for their choices. Also, the authors used primidone only in HEK cells, although they show higher basal activity in oocytes as well, why did the authors not perform parallel experiments for both splice variants?

10\) Figure 1: The authors assume that the co-expression of wild-type and mutant receptors (in 1:1 ratio) will lead to heteromeric channels. What is the experimental evidence for this assumption? Moreover, the fact that the mutations are heterozygote, according to Dyment et al., 2019, does not necessarily mean a heteromeric channels. Thus, it is not clear what the advantage is of these experiments.

11\) Figure 1---figure supplement 2: According to the present results, the agonist CIM0216 evokes a non-washable response in oocytes in all the concentrations. Thus, establishing a relevant dose-response under these conditions is quite challenging. The authors should perform a single dose recording normalized to the saturating concentration and not a step dose-response. More importantly, the mutant V990M seems to lose all sensitivity to the CIM in negative potentials. Alternatively, the data for CIM should be eliminated.

12\) Figure 1---figure supplement 3: The authors measure the Gi evoked TRPM3 inhibition of the wild type and mutants. Although the conclusion that the mutations do not interfere with the Gi inhibition seems correct, the experiment should be done at the relevant EC50 of each construct and not in the wild type saturating concentration.

13\) Figure 2: similar to the previous point, the authors should normalize the temperature response to the same PregS saturating level based on their dose-response (Figure 1). Using the saturating dose of the wild-type receptor is not comparable when the authors claim to a leftward shift in the mutant\'s dose-response.

14\) Figure 2---figure supplement 1: The authors should provide some recording examples to these basal currents. Based on Figure 2A-C, it seems all constructs have a similar baseline.

15\) Figure 3 and Figure 4: As mention previously, it is not clear what is the purpose of this specific splice variant to this study, and why HEK cells and calcium imaging. This data can be added as a supplement to Figure 1.
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Author response

> Summary:
>
> The physiological functions of TRPM3 ion channels are not well understood. TRPM3 has been shown to act as a peripheral nervous system mild temperature heat-sensor. However, the roles it might play in the central nervous system are less well known. Recently, single point mutations have been identified in TRPM3 from human patients with a neurodevelopmental disability and epilepsy. This finding suggests that TRPM3 channels may play a very important physiological role in normal aspects of motor control and cognition.
>
> This manuscript by Zhao at al., presents an initial characterization of the functional effects of these two mutations on the molecular physiology of hTRPM3. The findings show that both mutants produce a gain-of-function phenotype that partially explains the pathological effects of the mutations.
>
> Essential revisions:
>
> 1\) The authors use two \"commonly used\" splice variants of the channel but do not specify if these are the variants expressed in the brain in humans. It seems that both of those are not the same splice variant where the mutations were recently found (Dyment et al., 2019). The authors should perform the analysis on the same splice variant that was sequenced in human patients.

To our knowledge there is no information on which splice variants are expressed in the human brain. These mutations are identified in genomic DNA sequences and therefore are found in all splice variants, as neither mutation is located on an alternatively spliced exon. There are more than 17 splice variants of TRPM3 in mice and a similar number in humans; most of them have not been functionally characterized. The authors identifying these mutations did not perform any functional experiments; rather they chose an arbitrary splice variant as a reference sequence to assign numbers to the mutated residues. We chose the two best characterized splice variants to characterize these mutations, to ensure that the effect of the mutations are not specific to one arbitrarily chosen splice variant. We clarified this in the revised version.

> 2\) For the V990M and P1090Q, the authors explain that \"temperature sensitivity\" was affected (to different degrees), however, they have not measured temperature sensitivity, that is, the slope of the conductance vs. temperature curve. The authors should be careful to distinguish this measurement from the amplitude of the current at a fixed temperature, which is what they are measuring and may or may not have anything to do with changes in sensitivity.

We have performed new experiments for the revised version, where we measured TRPM3 currents in response to slower temperature ramps, and plotted the current increase as a function of temperature. Our data show that the P1092Q mutant showed a significantly steeper increase in currents than the V992M mutant with increasing temperature, and both mutants showed significantly steeper increase than wild type. The new data are shown in Figure 3 of the revised version.

> 3\) For the mutant in the pore (P1090Q), the authors should show if the effect of the mutant is also on the single-channel conductance. This is especially true to begin to distinguish the effects on temperature activation.

As the major effect of the P1090Q mutant was not increased current amplitudes, but rather increased sensitivity to heat and left shifted concentration response relationship to agonists, measuring single channel conductance would not explain the key effect of the mutation, and we felt that detailed single channel characterization of the mutations is beyond the scope of the manuscript. I would also like to refer to my phone conversation with Dr. Islas who confirmed that this experiment was not critical for the revised version.

> 4\) The effects of the mutations are characterized by comparing magnitude of the current elicited by ligands or temperature with the magnitude of the currents elicited by pregnenolone sulphate (PS), but the authors have not characterized the effects of the mutations on the sensitivity of the channels to PS. It is paramount that the authors show that the mutants have not affected activation by PS since this could severely bias the interpretation of the results.

It is not clear what the reviewers meant, we have performed PregS concentration dependence measurements, which were shown in Figure 1 and Figure 3 and the V990/992M mutation induced a larger left shift than the P1090/1092Q mutation. As the figures have been rearranged, these data are shown in Figure 1 and Figure 4 in the revised version.

> 5\) The interpretation that each one of the mutations affects heat or agonist activation preferentially is not well sustained. Without measuring the actual sensitivity to temperature, you cannot argue that it has been changed by the mutation. The same goes for sensitivity to agonist. Without knowing the binding site you cannot make an argument about sensitivity. Given that TRPM3 seems to be a channel that acts by allosterically coupling its different modalities of activation, and the fact that both mutations increase the basal activity of the channel to some degree, it the seems likely that both mutations just increase the basal open probability without actually affecting the sensitivity to temperature or to ligand. Given that these channels are gated by allosteric mechanisms, increasing the basal open probability will be reflected in increased fractions of current being activated by either temperature or ligand binding. Since the authors do not yet have a handle on the detailed effects of the mutations, they should be careful to offer mechanistic molecular explanations.

We agree with the reviewer that we do not have a full mechanistic explanation for the effect of the mutations; we have substantially rewritten the discussion and tried our best to be more careful with interpreting our data in the revised version. When referring to agonist sensitivity we meant the shift in the concentration response curve, and did not mean ligand binding, for which we agree with the reviewer that we need knowledge of the binding site. Overall, however, we do not believe that a simple increase in basal activity can explain the differences between the functional effects of the two mutations. The V990/992M mutation induced a larger increase in basal activity and a larger left shift in the PregS dose response than the P1090/1092Q mutation. If both mutants simply increased basal activity, i.e. the stability of the open state, then the V990/992M mutation would also have a larger effect on temperature activation than the P1090/1092Q mutation. This is however not the case, rather it is the opposite, the P1090/1092Q mutation had a larger effect on temperature activation than V990/992M. As mentioned earlier, in the revised version we also confirmed this finding with measuring the slope of the current increase which showed that the P1092Q mutant showed a significantly steeper increase in currents with increasing temperatures than V992M (Figure 3).

> 6\) Given that the heat sensitivity of TRPM3 might be relevant for central neurons, you may consider testing the PS sensitivity of the mutant channels at the body temperature of 37°C. Results from such experiments would dramatically boost the significance of the study. In addition, it is important to note that the elevated basal Ca^2+^ levels in the mutant-expressing cells may alter the chemo- and thermos- sensitivities indirectly, e.g., by affecting the levels of PIP2, which is known to regulate TRPM3. This should be discussed.

We have performed additional experiments at 37°C in the plate reader assay. As expected, the EC50 for PregS activation of the wild type channel shifted to the left. In both mutants however basal cytoplasmic Ca^2+^ levels became so high, that PregS did not induce any additional increase in cytoplasmic Ca^2+^. These new data are shown in Figure 1---figure supplement 3. We also applied primidone (50 μM) which decreased basal Ca^2+^ levels in both mutants at 37°C similar to that of the basal Ca^2+^ levels in cells transfected with the wild type channels. Primidone also decreased basal Ca^2+^ levels in cells transfected with wild type TRPM3 at 37°C, which is consistent with our data showing that increasing temperature to 37°C from room temperature induces channel activity. These new data are shown in Figure 1 Panels M-P. We have also discussed the possibility of indirect effects by the mutations via PIP2, and possible effects of increased Ca^2+^ levels on PIP2. The patch clamp and two electrode voltage clamp experiments were performed in the absence of Ca^2+^ therefore Ca^2+^ induced changes in PIP2 levels are unlikely in those experimental settings.

> 7\) The temperature-dependent gating described here should be thoroughly reviewed. TRPM3 is known to be activated by noxious heat, but in the current study, the channel is robustly activated by 30°C. Judging from the recordings in the Figure 2, it appeared that there was no temperature threshold for activation. Note that the temperature protocol appears to be slightly misaligned with the current traces, such that the currents started to increase prior to temperature elevations. The authors should also consider using the same experimental protocol and X/Y axis to compare WT and mutant channels.

Genetic deletion of TRPM3 leads to defects in noxious heat sensations, but the channel is known to be activated by temperature well below noxious temperatures; thus, our data are congruent with the literature. We explained this in the introduction of the revised version. The current increasing earlier than the temperature was a plotting error during file conversion, we fixed it in the revised version, but the reviewer is correct that there do not seem to be a threshold, as soon as the temperature increases the current starts increasing also. This is again consistent with data in the literature, the article first describing temperature activation of TRPM3 noted that TRPM3 currents increase when the recording temperature is increased from 15 to 26^o^C with a further increase of currents at 37^o^C (Vriens et al., 2011).

> 8\) In Figure 4, the experimental design is flawed. The effects of drug inhibition should be separated from those caused by temperature reduction (washout).

The purpose of applying primidone in Figure 4 (Figure 2 in the revised manuscript) was to accelerate return of the Ca^2+^ levels to baseline after increased temperature, not to test the effect of the drug per se. We mentioned in the main text, but we also clarify this in the figure legend.

> 9\) The authors analyze one splice variant in oocytes (using electrophysiology) and the second one in HEK cells using calcium imaging. The authors did not provide any reason for their choices. Also, the authors used primidone only in HEK cells, although they show higher basal activity in oocytes as well, why did the authors not perform parallel experiments for both splice variants?

We have provided a better justification for using two splice variants and performed experiments in *Xenopus oocytes* with primidone. The new data are shown in Figure 4---figure supplement 1A-E.

> 10\) Figure 1: The authors assume that the co-expression of wild-type and mutant receptors (in 1:1 ratio) will lead to heteromeric channels. What is the experimental evidence for this assumption? Moreover, the fact that the mutations are heterozygote, according to Dyment et al., 2019, does not necessarily mean a heteromeric channels. Thus, it is not clear what the advantage is of these experiments.

We did not say the channels were forming heteromers, as we agree with the reviewer that we cannot be certain of that without experimental evidence. We think this experiment is important as it presumable mimics the heterozygous condition, regardless of whether the mutant channels form heteromers. In heterozygous conditions one chromosome has the mutant the other chromosome has the wild type gene, and we think it is a reasonable assumption that they generate mRNA of the wild type and mutant channels in similar amounts. We clarified this in the revised version. Note that in the revised version the figure describing these data became Figure 4.

> 11\) Figure 1---figure supplement 2: According to the present results, the agonist CIM0216 evokes a non-washable response in oocytes in all the concentrations. Thus, establishing a relevant dose-response under these conditions is quite challenging. The authors should perform a single dose recording normalized to the saturating concentration and not a step dose-response. More importantly, the mutant V990M seems to lose all sensitivity to the CIM in negative potentials. Alternatively, the data for CIM should be eliminated.

We have removed the CIM0216 oocyte data from the revised version.

> 12\) Figure 1---figure supplement 3: The authors measure the Gi evoked TRPM3 inhibition of the wild type and mutants. Although the conclusion that the mutations do not interfere with the Gi inhibition seems correct, the experiment should be done at the relevant EC50 of each construct and not in the wild type saturating concentration.

We have performed experiments with M2 receptors using EC50 concentrations of PregS from wild type and mutant channels; the new data are shown in Figure 4---figure supplement 3G-K. The data are consistent with our initial assessment that interfering with Gβγ inhibition is not the major mechanism of overactivity in these mutants.

> 13\) Figure 2: similar to the previous point, the authors should normalize the temperature response to the same PregS saturating level based on their dose-response (Figure 1). Using the saturating dose of the wild-type receptor is not comparable when the authors claim to a leftward shift in the mutant\'s dose-response.

The oocyte experiments with temperature induced currents are moved to the supplement (Figure 4---figure supplement 2) as the new patch clamp experiments in HEK cells (Figure 3) convey a very similar message. The concentration response curves are left shifted in the mutants, therefore a saturating concentration for the wild type is also saturating for the mutants.

> 14\) Figure 2---figure supplement 1: The authors should provide some recording examples to these basal currents. Based on Figure 2A-C, it seems all constructs have a similar baseline.

This figure was a compilation of data from the original Figure 1, Figure 2 and Figure 1---figure supplement 2, example traces were provided in those figures. We have performed additional experiments with the TRPM3 inhibitor primidone in oocytes, which we show together in the revised manuscript with the summary of basal currents, providing additional representative traces in the same figure (Figure 4---figure supplement 1A-C).

> 15\) Figure 3 and Figure 4: As mention previously, it is not clear what is the purpose of this specific splice variant to this study, and why HEK cells and calcium imaging. This data can be added as a supplement to Figure 1.

There are several reasons we think these experiments are important. 1. The splice variant we used in the original Figure 3 and 4 (Figure 1 and Figure 2 in the revised MS) is the human orthologue of the best characterized mouse splice variant TRPM3a2. TRPM3 has a large number of splice variants (\>17), testing the effect of mutations all of them is not realistic, but we wanted to ensure that our data are not only valid on splice variant. 2. The oocyte experiments were performed in the absence of Ca^2+^ to avoid complications with Ca^2+^ induced inactivation. The Ca^2+^ imaging data show that a similar effect is also induced on Ca^2+^ signals evoked by TRPM3 activation. 3. As it was pointed out the CIM0216 dose response in oocytes is difficult to interpret, and our Ca^2+^ measurements show that the CIM0216 dose response is also left shifted. Nevertheless, our new HEK cell electrophysiology experiments (Figure 3) made the original Figure 2 with heat-induced currents in oocyte redundant; therefore, we moved that figure in the supplement (Figure 4---figure supplement 2).
